Used primarily in pharmaceutical research as a targeted protein degrader, particularly in oncology. It functions as a PROTAC (proteolysis-targeting chimera) by recruiting E3 ubiquitin ligase to specific disease-causing proteins, tagging them for degradation by the cell's proteasome system. This compound is especially investigated for its ability to degrade proteins involved in cancer cell proliferation and survival. Its design allows selective targeting of hard-to-treat intracellular proteins, making it a valuable tool in developing therapies for resistant or relapsed cancers. Also used in biochemical studies to probe protein function and validate drug targets.